- Home
- SIGA
as 01-21-2025 4:00pm EST
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 443.4M | IPO Year: | 1997 |
| Target Price: | N/A | AVG Volume (30 days): | 422.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | 1.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.26 - $12.83 | Next Earning Date: | 03-11-2025 |
| Revenue: | $173,731,386 | Revenue Growth: | 399.31% |
| Revenue Growth (this year): | 16.79% | Revenue Growth (next year): | 15.08% |
Latest SIGA Technologies Inc. News
SIGA Breaking Stock News: Dive into SIGA Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Siga Technologies Inc. (SIGA) Stock Dips While Market Gains: Key Facts
Zacks
6 days ago
Siga Technologies Inc. (SIGA) Advances But Underperforms Market: Key Facts
Pharmaceutical Technology
19 days ago
SIGA’s antiviral approved in Japan for orthopoxvirus treatment
Benzinga
20 days ago
Japan Approves SIGA Technologies Antiviral As First For Smallpox, Mpox
MT Newswires
20 days ago
SIGA Technologies Says Japan's Pharmaceutical Regulator Approves its Antiviral Treatment for Smallpox, MPox, Cowpox
GlobeNewswire
20 days ago
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
Zacks
a month ago
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Simply Wall St.
a month ago
Undiscovered Gems In The United States To Explore December 2024
Compare SIGA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SIGA SIGA Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.